This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/019818-2021">https://www.find-tender.service.gov.uk/Notice/019818-2021</a>

Tender

# Biological Sample Processing, Genotyping, and Storage

Our Future Health (Akeso&Co acting on behalf of)

F02: Contract notice

Notice identifier: 2021/S 000-019818

Procurement identifier (OCID): ocds-h6vhtk-02a73b

Published 13 August 2021, 6:15pm

# **Section I: Contracting authority**

# I.1) Name and addresses

Our Future Health (Akeso&Co acting on behalf of)

2 New Bailey, 6 Stanley Street

Manchester

M3 5JL

#### **Email**

OFH@akesoco.com

### **Telephone**

+44 2045291688

### Country

**United Kingdom** 

#### **NUTS** code

UK - United Kingdom

Internet address(es)

Main address

www.ourfuturehealth.org.uk

### I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

https://www.delta-esourcing.com/tenders/UK-UK-Manchester:-Research-laboratory-services./67M68523U5

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

https://www.delta-esourcing.com/

Tenders or requests to participate must be submitted to the above-mentioned address

# I.4) Type of the contracting authority

Other type

Health Research and Development

# I.5) Main activity

Other activity

Health research

# **Section II: Object**

# II.1) Scope of the procurement

### II.1.1) Title

Biological Sample Processing, Genotyping, and Storage

#### II.1.2) Main CPV code

• 73111000 - Research laboratory services

### II.1.3) Type of contract

Services

#### II.1.4) Short description

The scope of the procurement is receipt, processing and DNA extraction of blood samples from 5 million participants; design, manufacture and assessment of a high-throughput genome-wide genotype assay; the provision of a genotype service; and ultra-low temperature, long term storage of plasma, buffy coat, and DNA. The aim for commencement of these agreements is December 2021.

### II.1.5) Estimated total value

Value excluding VAT: £212,000,000

### II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

Maximum number of lots that may be awarded to one tenderer: 7

## II.2) Description

#### II.2.1) Title

Biological sample Receipt & Processing

Lot No

### 1 - England

### II.2.2) Additional CPV code(s)

• 71900000 - Laboratory services

### II.2.3) Place of performance

**NUTS** codes

- UKH East of England
- UKI London
- UKF East Midlands (England)
- UKG West Midlands (England)
- UKJ South East (England)
- UKK South West (England)
- UKE Yorkshire and the Humber
- UKD North West (England)
- UKC North East (England)

Main site or place of performance

EAST OF ENGLAND, LONDON, EAST MIDLANDS (ENGLAND), WEST MIDLANDS (ENGLAND), SOUTH EAST (ENGLAND), SOUTH WEST (ENGLAND), YORKSHIRE AND THE HUMBER, NORTH WEST (ENGLAND), NORTH EAST (ENGLAND)

#### II.2.4) Description of the procurement

The aim of Our Future Health is to recruit up to five million adults from across the UK to take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases.

We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services to process 2 x 6 ml EDTA blood samples from each of the 5 million participants with the aim to commence from December 2021. Processing will include barcode scanning receipt, fraction separation by centrifugation, aliquoting of plasma and buffy coat, DNA extraction, quantification and normalisation, temporary storage at low and ultra-low temperatures, effective IT and LIMS for tracking all child aliquots, and shipment of specimens for long term storage or genotyping.

### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

### II.2.6) Estimated value

Value excluding VAT: £54,500,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

48

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 12 months (per renewal) subject to a maximum Term of 7 years in total

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.delta-esourcing.com/respond/67M68523U5">https://www.delta-esourcing.com/respond/67M68523U5</a>

Access code for Lot 1 is; 67M68523U5

# II.2) Description

### II.2.1) Title

Biological sample Receipt & Processing

Lot No

2 - Scotland

### II.2.2) Additional CPV code(s)

• 71900000 - Laboratory services

### II.2.3) Place of performance

**NUTS** codes

· UKM - Scotland

Main site or place of performance

**SCOTLAND** 

### II.2.4) Description of the procurement

The aim of Our Future Health is to recruit up to five million adults from across the UK to take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and a small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases.

We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services to process 2 x 6 ml EDTA blood samples from each of the 5 million participants with the aim to commence from December 2021. barcode scanning receipt, fraction separation by centrifugation, aliquoting of plasma and buffy coat, DNA extraction, quantification and normalisation, samples at with temporary storage at low and ultra-low temperatures, effective IT and LIMS for tracking all child aliquots, and shipment of specimens for long term storage or genotyping.

#### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

Value excluding VAT: £5,200,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

48

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 12 months (per renewal) subject to a maximum Term of 7 years in total.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.delta-esourcing.com/respond/639AY67J52">https://www.delta-esourcing.com/respond/639AY67J52</a>

Access code for Lot 2 is 639AY67J52

# II.2) Description

### II.2.1) Title

Biological sample Receipt & Processing

Lot No

#### 3 - Wales

### II.2.2) Additional CPV code(s)

• 71900000 - Laboratory services

#### II.2.3) Place of performance

**NUTS** codes

• UKL - Wales

Main site or place of performance

#### **WALES**

### II.2.4) Description of the procurement

The aim of Our Future Health is to recruit up to five million adults from across the UK to take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases. We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services to process 2 x 6 ml EDTA blood samples from each of the 5 million participants with the aim to commence from December 2021. Processing will include barcode scanning receipt, fraction separation by centrifugation, aliquoting of plasma and buffy coat, DNA extraction, quantification and normalisation, temporary storage at low and ultra-low temperatures, effective IT and LIMS for tracking all child aliquots, and shipment of specimens for long

term storage or genotyping.

### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

Value excluding VAT: £3,200,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

48

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 12 months (per renewal) subject to a maximum Term of 7 years in total.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents

# II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.deltaesourcing.com/respond/639AY67J52">https://www.deltaesourcing.com/respond/639AY67J52</a>

Access code for Lot 3 is 639AY67J52

### II.2) Description

### II.2.1) Title

Biological sample Receipt & Processing

Lot No

4 - Northern Ireland

#### II.2.2) Additional CPV code(s)

• 71900000 - Laboratory services

### II.2.3) Place of performance

**NUTS** codes

• UKN - Northern Ireland

Main site or place of performance

#### NORTHERN IRELAND

### II.2.4) Description of the procurement

The aim of Our Future Health is to recruit up to five million adults from across the UK to take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases.

We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services to process 2 x 6 ml EDTA blood samples from each of the 5 million participants with the aim to commence from December 2021. Processing will include barcode scanning receipt, fraction separation by centrifugation, aliquoting of plasma and buffy coat, DNA extraction, quantification and normalisation, temporary storage at low and ultra-low temperatures, effective IT and LIMS for tracking all child aliquots, and shipment of specimens for long term storage or genotyping.

### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

### II.2.6) Estimated value

Value excluding VAT: £2,100,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

48

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 12 months (per renewal) subject to a maximum Term of 7 years in total.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.delta-esourcing.com/respond/639AY67J52">https://www.delta-esourcing.com/respond/639AY67J52</a>

Access code for Lot 4 is 639AY67J52

# II.2) Description

### II.2.1) Title

Genotype assay - design/manufacture

Lot No

5

# II.2.2) Additional CPV code(s)

• 73111000 - Research laboratory services

### II.2.3) Place of performance

**NUTS** codes

- · UKH East of England
- UKI London
- UKF East Midlands (England)
- UKG West Midlands (England)

- UKL Wales
- UKM Scotland
- UKJ South East (England)
- UKK South West (England)
- UKE Yorkshire and the Humber
- UKD North West (England)
- UKC North East (England)

Main site or place of performance

EAST OF ENGLAND, LONDON, EAST MIDLANDS (ENGLAND), WEST MIDLANDS (ENGLAND), WALES, SCOTLAND, SOUTH EAST (ENGLAND), SOUTH WEST (ENGLAND), YORKSHIRE AND THE HUMBER, NORTH WEST (ENGLAND), NORTH EAST (ENGLAND)

### II.2.4) Description of the procurement

NOTE: The design and manufacture can happen outside of the Place of Performance but all genotyping and data processing of Customer-supplied quality control must be conducted within the boundaries of the Place of Performance.

The aim of Our Future Health is to recruit up to five million adults from across the UK to take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases.

We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at

higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services to design, manufacture and quality control assess a genotype assay that could be applied to process 5 million participants with the aim to commence an agreement from December 2021.

#### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

Value excluding VAT: £56,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

48

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 12 months (per renewal) subject to a maximum Term of 7 years in total.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.delta-esourcing.com/respond/3XGB99977T">https://www.delta-esourcing.com/respond/3XGB99977T</a>

Access code for Lot 5 is 3XGB99977T

# II.2) Description

### II.2.1) Title

Genotyping service provision

Lot No

6

### II.2.2) Additional CPV code(s)

• 73111000 - Research laboratory services

### II.2.3) Place of performance

**NUTS** codes

- UKH East of England
- UKI London
- UKF East Midlands (England)
- UKG West Midlands (England)
- UKL Wales
- · UKM Scotland
- UKJ South East (England)
- UKK South West (England)
- UKE Yorkshire and the Humber

- UKD North West (England)
- UKC North East (England)

Main site or place of performance

EAST OF ENGLAND, LONDON, EAST MIDLANDS (ENGLAND), WEST MIDLANDS (ENGLAND), WALES, SCOTLAND, SOUTH EAST (ENGLAND), SOUTH WEST (ENGLAND), YORKSHIRE AND THE HUMBER, NORTH WEST (ENGLAND), NORTH EAST (ENGLAND)

### II.2.4) Description of the procurement

The aim of Our Future Health is to recruit up to five million adults from across the UK to take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases.

We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services to genotype 5 million DNA samples using the genotype assay designed and manufactured by the awarded supplier of Lot 5, conduct genotype calling, and provide all results back to the Our Future Health.

#### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement

documents

### II.2.6) Estimated value

Value excluding VAT: £26,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

48

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 12 months (per renewal) subject to a maximum Term of 7 years in total.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents

# II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.delta-">https://www.delta-</a> esourcing.com/respond/67M68523U5

Access code for Lot 6 is 67M68523U5

# II.2) Description

### II.2.1) Title

Sample Storage and Access Management

Lot No

7

### II.2.2) Additional CPV code(s)

• 73111000 - Research laboratory services

### II.2.3) Place of performance

**NUTS** codes

- UKH East of England
- UKI London
- UKF East Midlands (England)
- UKG West Midlands (England)
- UKL Wales
- UKJ South East (England)
- UKK South West (England)
- UKE Yorkshire and the Humber
- UKD North West (England)
- UKC North East (England)

Main site or place of performance

EAST OF ENGLAND, LONDON, EAST MIDLANDS (ENGLAND), WEST MIDLANDS (ENGLAND), WALES, SOUTH EAST (ENGLAND), SOUTH WEST (ENGLAND), YORKSHIRE AND THE HUMBER, NORTH WEST (ENGLAND), NORTH EAST (ENGLAND)

# II.2.4) Description of the procurement

he aim of Our Future Health is to recruit up to five million adults from across the UK to

take part in the largest research study of its kind. Participants will be asked to provide information about their health and lifestyles and small sample of their blood.

We will ask for permission to combine the information and samples that they give us with existing information about them, including their health records. Adding these additional types of information will help to build a more comprehensive picture of health and wellbeing that could be relevant to understanding what changes people's risk of disease.

Combining these multiple sources of health and health-relevant information, including genetic data, will create an incredibly detailed picture that represents the whole of the UK. Researchers will use this information to make new discoveries about human health and diseases.

We will use the health information, including genetic data, to calculate disease risk scores for participants in Our Future Health where possible. Based on these risk profiles, it might be possible to better identify individuals who are at higher risk of developing certain diseases. This will provide an opportunity to test the potential of new diagnostic tests or treatments as they are discovered and to see how effective they could be for people at higher risk of certain diseases. This will also mean Our Future Health can facilitate research addressing important questions about the potential uses of new 'genetic risk scores' in health care.

In order to achieve this aim, Our Future Health needs to contract for services for automated, ultra-low temperature, long term storage of up to 45 million cryovials of plasma, buffy coat, and DNA as well as access management of these samples.

#### II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### II.2.6) Estimated value

Value excluding VAT: £65,000,000

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

60

This contract is subject to renewal

Yes

Description of renewals

Extensions of up to 36 months (per renewal) subject to a maximum Term of 14 years in total.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: Yes

Description of options

The contract includes options to provide additional services which are detailed in the procurement documents.

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2.14) Additional information

To respond to this opportunity please click here: <a href="https://www.delta-esourcing.com/respond/4V872ZFEMH">https://www.delta-esourcing.com/respond/4V872ZFEMH</a>

Access code for Lot 7 is 4V872ZFEMH

# Section III. Legal, economic, financial and technical information

# III.1) Conditions for participation

### III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

### III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

### Section IV. Procedure

## **IV.1) Description**

### IV.1.1) Type of procedure

Open procedure

### IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

# IV.2) Administrative information

### IV.2.1) Previous publication concerning this procedure

Notice number: 2021/S 000-008138

# IV.2.2) Time limit for receipt of tenders or requests to participate

Date

16 September 2021

Local time

5:00pm

### IV.2.4) Languages in which tenders or requests to participate may be submitted

English

# IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 5 (from the date stated for receipt of tender)

#### IV.2.7) Conditions for opening of tenders

Date

17 September 2021

Local time

8:00am

# **Section VI. Complementary information**

# VI.1) Information about recurrence

This is a recurrent procurement: No

## VI.2) Information about electronic workflows

Electronic invoicing will be accepted

Electronic payment will be used

# VI.3) Additional information

The contracting authority considers that this contract may be suitable for economic operators that are small or medium enterprises (SMEs). However, any selection of tenderers will be based solely on the criteria set out for the procurement.

For more information about this opportunity, please visit the Delta eSourcing portal at:

https://www.delta-esourcing.com/tenders/UK-UK-Manchester:-Research-laboratory-services./67M68523U5

To respond to this opportunity, please click here:

https://www.delta-esourcing.com/respond/67M68523U5

GO Reference: GO-2021813-PRO-18735778

# VI.4) Procedures for review

VI.4.1) Review body

Akeso & Co

21 Bloomsbury Way

London

WC1A 2TH

Country

United Kingdom

Internet address

https://www.akesoco.com/